Abiraterone acetate (Zytiga®) for mCRPC post ADT
Pharmacoeconomic evaluation of Abiratone acetate (Zytiga®) for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
Rapid Review
| Commenced | Completed | Outcome |
| 03/01/2013 | 01/02/2013 | Full Pharmacoeconomic Evaluation Recommended. |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 26/09/2013 | 07/03/2014 | Reimbursement not recommended at the submitted price. |
Abiraterone (Zytiga) pre-chemotherapy Summary
December 2015
The HSE has approved reimbursement following confidential price negotiations.